Last reviewed · How we verify
Augmenting: Antidepressant + Bupropion-SR
Bupropion-SR augments antidepressant therapy by inhibiting norepinephrine and dopamine reuptake, addressing residual depressive symptoms in patients with incomplete response to initial antidepressant monotherapy.
Bupropion-SR augments antidepressant therapy by inhibiting norepinephrine and dopamine reuptake, addressing residual depressive symptoms in patients with incomplete response to initial antidepressant monotherapy. Used for Major depressive disorder with incomplete response to initial antidepressant monotherapy, Treatment-resistant depression.
At a glance
| Generic name | Augmenting: Antidepressant + Bupropion-SR |
|---|---|
| Sponsor | VA Office of Research and Development |
| Drug class | Norepinephrine-dopamine reuptake inhibitor (NDRI); antidepressant augmentation strategy |
| Target | Norepinephrine transporter (NET); dopamine transporter (DAT) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Mental Health |
| Phase | Phase 3 |
Mechanism of action
This combination strategy leverages bupropion's unique mechanism as a norepinephrine-dopamine reuptake inhibitor (NDRI) to enhance the effects of serotonergic antidepressants. By adding dopaminergic and noradrenergic activity to existing serotonergic therapy, the augmentation approach targets multiple neurotransmitter systems simultaneously, potentially improving efficacy in treatment-resistant depression. Bupropion-SR (sustained-release) formulation provides steady-state levels suitable for adjunctive use.
Approved indications
- Major depressive disorder with incomplete response to initial antidepressant monotherapy
- Treatment-resistant depression
Common side effects
- Insomnia
- Dry mouth
- Headache
- Nausea
- Agitation
- Seizures (dose-dependent)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: